(Q24244406)

4

0 references

Elad Goldberg

2

object named as

Elad Goldberg

0 references

Camilo J Acosta

3

object named as

Camilo J Acosta

0 references

Abigail Fraser

Cochrane Database of Systematic Reviews

1

object named as

Abigail Fraser

0 references

publication date

18 July 2007

0 references

published in

0 references

cites work

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

A seven-year field trial of two typhoid vaccines in Guyana

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Safety and efficacy of combined meningococcal and typhoid vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Typhoid fever in Bangladesh: implications for vaccination policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Typhoid fever in children aged less than 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Vaccines for preventing typhoid fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

Immunogenicity of Salmonella typhi Ty21a vaccine for young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

7 January 2021

Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

7 January 2021

Typhoid Vi: a less reactogenic vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

7 January 2021

Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001261.PUB2

7 January 2021